New guide on biosimilar medicines for healthcare professionals
Increasing understanding of biosimilar medicines
The European Medicines Agency (EMA) and the European Commission have published an information guide for healthcare professionals on biosimilar medicines. Biosimilars are biological medicines that are highly similar in all essential aspects to a biological medicinethat has already been authorised.
The objective of the guide is to provide healthcare professionals with reference information on both the science and regulation underpinning the use of biosimilars.
“Today, biosimilars are an integral part of the effective biological therapies available in the EU,” said Professor Guido Rasi, EMA’s Executive Director recently. “Given the role of healthcare professionals on the front line of patient care, it is vital that they have access to reliable information on these medicines: what they are and how they are developed, approved and monitored.”
The guide is a joint initiative of EMA and the European Commission. It was developed in collaboration with EU scientific experts, in response to requests from healthcare professionals. Organisations from across the EU representing doctors, nurses, pharmacists and patients have also shared useful views, to ensure that the guide adequately addresses questions relevant to healthcare professionals.
The guide was launched recently at the European Commission’s third stakeholder event on biosimilar medicines, a discussion forum that provides a platform for stakeholders interested in biosimilars, including healthcare professionals, patients, payers, regulators and industry.
Presenting the guide at the launch, Dr Juan Garcia Burgos, head of EMA’s Public Engagement Department emphasised that “this comprehensive reference material is a joint effort to support information and continuous education of healthcare professionals in the EU, and facilitate dialogue with patients.”
The EU has pioneered the regulation of biosimilar medicines by establishing a solid framework for their approval and by shaping biosimilar development globally.
Since the EU approved the first biosimilar in 2006, the evidence gained from clinical experience shows that biosimilars approved in the EU are as safe and effective in all their approved indications as other biological medicines. To date, the Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended 28 biosimilars for use in the EU.
|New guide onbiosimilar medicines for healthcare professionals - Increasing understanding ofbiosimilar medicines||(English only)||05/05/2017|
Latest News from
European Semester Spring Package: Sustaining a green and sustainable recovery in the face of increased uncertainty24/05/2022 10:25:00
The European Commission's 2022 European Semester Spring Package provides Member States with support and guidance two years on from the first impact of the COVID-19 pandemic and in the midst of Russia's ongoing invasion of Ukraine.
Commission (Eurostat) publishes 2022 report on Sustainable Development Goals in the European Union24/05/2022 09:25:00
Eurostat, the statistical office of the European Union, yesterday published the ‘Sustainable development in the European Union – 2022 monitoring report on progress towards the SDGs in an EU context', which provides a statistical overview of progress towards the Sustainable Development Goals (SDGs) in the EU.
State aid: Commission approves €16 million Finnish scheme to support farmers in context of Russia's invasion of Ukraine23/05/2022 16:33:00
The European Commission has approved a €16 million Finnish scheme to support the agricultural sector in the context of Russia's invasion of Ukraine.
Hong Kong: EU report sees a continued deterioration of fundamental freedoms23/05/2022 15:25:00
The European Commission and the High Representative recently (20 May 2022) reported on political and economic developments in the Hong Kong Special Administrative Region.
Increased support for EU farmers through rural development funds23/05/2022 14:33:00
The European Commission proposed an exceptional measure funded by the European Agricultural Fund for Rural Development (EAFRD) to allow Member States to pay a one-off lump sum to farmers and agri-food businesses affected by significant increases in input costs.
Macao: EU report highlights increasing challenges to political rights and fundamental freedoms23/05/2022 13:25:00
The European Commission and the High Representative recently (20 May 2022) reported on political and economic developments in the Macao Special Administrative Region, covering 2021.
EU disburses €600 million in Macro-Financial Assistance to Ukraine23/05/2022 12:38:00
The European Commission, on behalf of the EU, recently (20 May 2022) disbursed €600 million in Macro-Financial Assistance (MFA) to Ukraine. Following Russia's unprovoked and unjustified invasion, this urgent financial support helps Ukraine address its acute financing gap related to its exceptional humanitarian and defence needs.
State aid: Commission approves €500 million Luxembourgish scheme to support companies in context of Russia's invasion of Ukraine23/05/2022 11:33:00
The European Commission has approved a €500 million Luxembourgish guarantee scheme to support companies across sectors in the context of Russia's invasion of Ukraine.
Remarks by Executive Vice-President Dombrovskis and Commissioner Gentiloni at the European Semester 2022 Spring Package press conference23/05/2022 10:38:00
Remarks given by Executive Vice-President Dombrovskis and Commissioner Gentiloni at the European Semester 2022 Spring Package press conference.
EIB Board approves €4 billion credit line along with the EMBRACE Advisory Platform to support the integration of refugees from Ukraine in EU countries20/05/2022 09:25:00
The Board of Directors of the European Investment Bank (EIB) recently (18 May 2022) approved a €4 billion credit line (or programme loan) to help national authorities, cities, regions and local communities in all EU Member States address urgent investment needs and help welcome and integrate people fleeing the war against Ukraine.